At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
Albuterol +1 moredrug
Likely dose
Albuterol 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Modifying Genes in Cystic Fibrosis: The Beta-2 Adrenergic Receptors and Epithelial Na+ Channels
In Brief
A clinical study evaluating Albuterol and Placebo saline for Cystic Fibrosis and Healthy. Completed, enrolled 32 participants across 1 site.
Detailed Summary
Our aims were to determine if exhaled breath condensate (EBC) could detect differences in ion regulation between cystic fibrosis (CF) and healthy and measure the effect of the albuterol on EBC ions in these populations. We hypothesized EBC chloride and sodium would be lower in CF patients at baseline and that albuterol would decrease EBC sodium and increase EBC chloride.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis, Healthy
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
Primary CompletionJul 2012
Study CompletionJan 2013
First PostedJun 2013
TodayJul 2026
First PostedJun 19, 2013
Enrollment StartMay 1, 2009
Primary CompletionJul 1, 2012
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 13.0 years ago
Interventions
Albuteroldrug
2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
Placebo salinedrug
nebulized 3mL normal saline) using a Power Neb2 nebulizer